The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Comparison of incidence and average cost per toxicity in patients treated with nivolumab and pembrolizumab.
 
Neil Thomas Mason
Stock and Other Ownership Interests - Interpares Biomedicine
 
Scott Joseph Antonia
Stock and Other Ownership Interests - Cellular Biomedicine Group
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Merck
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Merck
Travel, Accommodations, Expenses - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Merck
 
Nikhil I. Khushalani
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Castle Biosciences; EMD Serono
Research Funding - Bristol-Myers Squibb (Inst); Eisai (Inst); GlaxoSmithKline; Merck (Inst); NCCN (Inst); Novartis (Inst); Pfizer (Inst); Threshold Pharmaceuticals (Inst); TRACON Pharma (Inst)
 
Howard L. McLeod
Stock and Other Ownership Interests - Cancer Genetics; Interpares Biomedicine
Consulting or Advisory Role - Cancer Genetics; Gentris; NIH/NCI; Saladax Biomedical